PATIDEGIB

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C29H48N2O3S
Molecular Weight	504.768
Optical Activity	UNSPECIFIED
Defined Stereocenters	11 / 11
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[H][C@@]12C[C@H](C)CN[C@@]1([H])[C@@H](C)[C@@]3(CC[C@]4([H])C(C[C@@]5([H])[C@@]4([H])CC[C@]6([H])C[C@@H](CC[C@]56C)NS(C)(=O)=O)=C(C)C3)O2

InChI

InChIKey=HZLFFNCLTRVYJG-WWGOJCOQSA-N

InChI=1S/C29H48N2O3S/c1-17-12-26-27(30-16-17)19(3)29(34-26)11-9-22-23-7-6-20-13-21(31-35(5,32)33)8-10-28(20,4)25(23)14-24(22)18(2)15-29/h17,19-23,25-27,30-31H,6-16H2,1-5H3/t17-,19+,20+,21+,22-,23-,25-,26+,27-,28-,29-/m0/s1

HIDE SMILES / InChI

Molecular Formula	C29H48N2O3S
Molecular Weight	504.768
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	11 / 11
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/mesh/67541444 | https://www.ncbi.nlm.nih.gov/pubmed/19522463 | https://pellepharm.com/science

FIN-6 (PATIDEGIB, IPI-926), a semisynthetic derivative of alkaloid cyclopamine, is a G protein-coupled receptor Smoothened (Smo) inhibitor with antineoplastic activity. Smo is a key signaling transmembrane protein in the Hedgehog signaling pathway which plays an important role in the proliferation of neuronal precursor cells in the developing cerebellum and other tissues. FIN-6 (PATIDEGIB, IPI-926) is under development for Gorlin syndrome, basal cell carcinomas, and other potential indications.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Smoothened homolog 20 Target ID: Q99835 Gene ID: 6608.0 Gene Symbol: SMO Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/24634412 \| https://www.ncbi.nlm.nih.gov/pubmed/21203400	Inhibitor 8297
Smoothened homolog 20 Target ID: CHEMBL5971 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19522463\|https://adisinsight.springer.com/drugs/800029135	Inhibitor 8297		1.4 nM [IC50]

PubMed

Title	Date	PubMed
Discovery of a potent and orally active hedgehog pathway antagonist (IPI-926).	2009 Jul 23	19522463
Self-renewal of acute lymphocytic leukemia cells is limited by the Hedgehog pathway inhibitors cyclopamine and IPI-926.	2010 Dec 28	21203400
Phase I study of the Hedgehog pathway inhibitor IPI-926 in adult patients with solid tumors.	2013 May 15	23575478
Hedgehog pathway inhibition in chondrosarcoma using the smoothened inhibitor IPI-926 directly inhibits sarcoma cell growth.	2014 May	24634412
A Phase I Study of FOLFIRINOX Plus IPI-926, a Hedgehog Pathway Inhibitor, for Advanced Pancreatic Adenocarcinoma.	2016 Mar	26390428

Substance Class	Chemical Created by `admin` on `Fri Dec 15 19:16:17 UTC 2023` Edited by `admin` on `Fri Dec 15 19:16:17 UTC 2023`
Record UNII	JT96FPU35X
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

PATIDEGIB

Official Name

English

IPI 926

Code

English

patidegib [INN]

Common Name

English

METHANESULFONAMIDE, N-((2S,3R,3'R,3AS,4'AR,6S,6'AR,6'BS,7AR,12'AS,12'BS)-2',3',3A,4,4',4'A,5,5',6,6',6'A,6'B,7,7',7A,8',10',12',12'A,12'B-EICOSAHYDRO-3,6,11',12'B-TETRAMETHYLSPIRO(FURO(3,2-B)PYRIDINE-2(3H),9'(1'H)-NAPHTH(2,1-A)AZULEN)-3'-YL)-

Common Name

English

PATIDEGIB [USAN]

Common Name

English

FIN-5

Code

English

IP9 FREE BASE

Code

English

IPI-926 FREE BASE

Code

English

SARIDEGIB

Common Name

English

Patidegib [WHO-DD]

Common Name

English

IPI-926

Code

English

IP-9

Code

English

Classification Tree Code System Code

FDA ORPHAN DRUG

587917